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Background: Tyrosine kinase inhibitors (TKIs) have been associated with elevated TSH as a drug class effect. Prior
studies of vandetanib in adults with medullary thyroid carcinoma (MTC) described an increase in levothyroxine (LT)
requirement. We studied TSH, free T4, and LT dosing in children and adolescents enrolled in the phase I/II trial of
vandetanib for medullary thyroid cancer (MTC)
Methods: Data from 13 patients with multiple endocrine neoplasia type 2B (MEN 2B) and MTC were analyzed [6 M,
7 F, median age 13.0 y (9.1-17.3)] Eleven patients (85%) had undergone prior thyroidectomy and all received single-drug
therapy with vandetanib for > 6 months. Confirmed compliance with vandetanib (67–150 mg/m2/day) and LT was a
necessary inclusion criterion.
Results: While on vandetanib treatment, all 11 athyerotic patients exhibited significantly increased TSH levels. The
baseline TSH level was 4.37 mclU/ml (0.08 - 23.30); in comparison, the first peak TSH concentration on vandetanib
was 15.70 mclU/ml (12.50 - 137.00, p = 0.0010). The median time to reach the initial peak of elevated TSH was
1.8 months (0.3 - 9.3). Free T4 levels remained within the normal reference range. An increase from a baseline LT
dose of 91 mcg/m2/day (±24) to 116 mcg/m2/day (±24) was required in order to resume normative TSH levels
(p = 0.00005), equal to an increase of 36.6% (±16.56) in the dosage of LT in mcg/day. For the 2 patients with intact
thyroid glands, free T4 and TSH remained normal over a combined 6 patient years of follow up.
Conclusions: In our cohort of pediatric MTC patients, athyreotic patients with preexisting hypothyroidism developed
increased TSH and reduced free T4 during the first few months of treatment with vandetanib, necessitating an increase
in LT dosage. Additional patients with normal thyroid function before treatment and intact glands (n = 2) maintained
normal thyroid function tests during treatment. Elevated TSH in athyreotic patients may be due to an indirect effect of
vandetanib on the metabolism of thyroid hormone, or to altered TSH sensitivity at the pituitary. Proper recognition and
management of abnormal thyroid hormone levels is critical in growing children on TKIs.
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Table 1 Patient Characteristics
Number of patients 13
Gender (male/female) 6/7
Age at start of enrollment on clinical
trial (median, range)
13.0 years (9.1-17.3)
RET mutation M918T (n = 13)
Baseline LT dose 100 mcg/day (57–200)
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Hereditary medullary thyroid carcinoma (MTC) is a mani-
festation of multiple endocrine neoplasia (MEN) type 2A
and MEN 2B syndromes caused by germline, activating
mutations in the RET (REarranged during Transfection)
proto-oncogene (10q11.2). MTC accounts for 5-10% of all
pediatric thyroid malignancies and its annual incidence is
0.3-2 cases per 106 children (1 M: 1 F) [1-3].
Only 25% of MTC cases are hereditary (Familial MTC
(FMTC), MEN2A, MEN2B) while the majority, 75% of
MTC cases, are sporadic. Hereditary MTC is multifocal,
bilateral, indolent and usually presents with metastasis
at the time of diagnosis. If diagnosed while the tumor is
confined to the thyroid, MTC has a favorable prognosis
(10 year survival rate 70-80%) [4]. Common sites of meta-
static disease include cervical and mediastinal lymph
nodes, as well as lungs, liver, and bone; in the case of
metastatic disease the 10 year survival rate drops to ap-
proximately 40% [4-7]. Metastatic or locally advanced
MTC is unresponsive to cytotoxic chemotherapy or radi-
ation [4,8]. Targeted therapy with Tyrosine Kinase inhibi-
tors (TKIs) are now approved to treat progressive and
advanced MTC. TKIs compete with the ATP-binding do-
mains of the TK catalytic unit inhibiting the activation of
oncogenic intracellular signaling pathways [9]. Vandetanib
(Caprelsa, Astra Zeneca Pharmaceuticals) is an orally bio-
available multi-RTK (receptor Tyrosine kinase) inhibitor
that blocks the mutant RET gene product and has anti-
tumor activity in adults with hereditary MTC [10,11]. At
the National Cancer Institute, a phase I/II trial of vandeta-
nib for children and adolescents with MTC was conducted
to define a recommended dose and assess antitumor activ-
ity, as described by Fox et al. [12]. A common non-dose
limiting toxicity was TSH elevation necessitating an in-
crease in levothyroxine (LT) dosage – however, this was
only noted in athyreotic patients who were previously on a
stable dose. TKIs have been associated with elevated TSH
as a drug class effect [13]; two prior studies of vandetanib
in adults with MTC described an increase in LT require-
ment [14,15]. Little is known about the effect of vandeta-
nib on thyroid hormone levels in children. Our objective
was to describe the TSH and free T4 levels and LT dosing
in children and adolescents enrolled in the phase I/II trial
of vandetanib for Multiple Endocrine Neoplasia Type 2B
(MEN 2B) and MTC, NCT00514046.
Methods
Data from 13 patients with MEN 2B and MTC were an-
alyzed [6 M, 7 F, median age 13.0 y (9.1-17.3)] (Table 1).
Patients were enrolled in the phase I/II trial of vandeta-
nib for Multiple Endocrine Neoplasia Type 2B (MEN 2B)
and MTC, NCT00514046. Informed consent from the pa-
tients’ parents (and assent from older children) was ob-
tained for all patients. Eleven patients (85%) had undergoneprior thyroidectomy and all received single-drug therapy
with vandetanib for > 6 months. Confirmed compliance
with vandetanib (67–150 mg/m2/day) and LT was a ne-
cessary inclusion criterion (Table 1). Patients were
instructed to take LT on an empty stomach and not with
other medications or calcium/soy containing products.
One patient was excluded due to non-compliance with his
replacement with LT. Data were analyzed using paired
t-tests for normally distributed data and the Wilcoxon
signed rank test for non-parametric data, and are reported
as mean (±SD) or median (range).Results
While on vandetanib treatment, all 11 athyreotic patients
exhibited significantly increased TSH levels. The baseline
TSH level was 4.37 mclU/ml (0.08 - 23.30). In comparison,
the first peak TSH concentration on vandetanib was
15.70 mclU/ml (12.50 - 137.00, p = 0.0010) (Figure 1).
The median time it took to reach the first peak of elevated
TSH was 1.8 months (0.3 - 9.3). Free T4 levels remained
within the normal reference range, yet significantly de-
creased from baseline levels of 1.47 ng/dL (±0.21) to
1.27 ng/dL (±0.30) when measured at the time of max-
imum TSH (p = 0.039) (Figure 2). TSH levels normalized
after subsequent increases in LT dose. An increase from a
baseline LT dose of 91 mcg/m2/day (±24) to 116 mcg/m2/
day (±24) was required in order to resume normative TSH
levels (p = 0.00005), (Figure 3), equal to an increase of
36.6% (±16.56) in the dosage of LT in mcg/day. There
were no clinical sequelae as a result of the elevations in
TSH. Thyroid hormone levels increased, either due to a
change in LT dose, or in one patient, due to vandetanib
being held for oral surgery without adjustment of the LT
dose to account for the effect of the TKI. Linear growth
was closely monitored for the duration of the study. The
median percentile of height for age at baseline was 30
(<3-96)%, and increased to 55 (<3-96)% at the last
evaluation (P = 0.03). The median percentile of weight
for age at baseline was 9 (<3-96)% and increased to 20
(<3-91)% at last evaluation (P = 0.48). For the 2 patients
with thyroid glands still intact, free T4 averaged 1.17 ±
0.15, (normal range 0.8-1.5 ng/dL) and TSH levels aver-
aged 3.48 ± 2.18, (normal range 0.4-4 mclU/ml) over a
combined 6 patient years of follow up.
Figure 1 TSH levels prior to initiation of vandetanib in
thyroidectomized patients compared to first peak TSH
concentration on study p = 0.0010. Figure 3 Dose of LT (mcg/m2/day at baseline vs. dose required
in order to resume normative TSH in thyroidectomized patients,
p = (p = 0.00005).
Lodish et al. International Journal of Pediatric Endocrinology 2015, 2015:3 Page 3 of 5
http://www.ijpeonline.com/content/2015/1/3Discussion
Innovative therapeutic agents that target genetic alterations
(selective cancer therapy) associated with the development
of MTC seem promising to treat progressive and advanced
MTC [16]. Even if TKIs combine a high therapeutic win-
dow with less toxicity than conventional chemotherapy,
vandetanib’s adverse effects varied in respect to the admin-
istered dose and included rash, nausea, hypertension, head-
ache, ECG QTc prolongation and endocrine effects [17]. In
a randomized controlled trial of vandetanib for adults with
MTC in which 90% of patients enrolled had prior thyroid-
ectomy, increased dosing of LT was required in 49.3% of
vandetanib treated patients compared to 17.2% of placebo-
treated patients [14]. In our cohort of pediatric MTC
patients, patients who were rendered hypothyroid after
thyroidectomy developed increased TSH and reduced
free T4 during the first few months of treatment with
vandetanib, necessitating an increase in LT dosage. Over
the duration of this ongoing study, we continue to adjust
LT dosing individualized to each patient as dosages ofFigure 2 Free T4 levels prior to initiation of vandetanib in
thyroidectomized patients compared to levels at first peak
TSH concentration, p = 0.039.TKIs are altered, and patients grow and progress through
puberty. Interestingly, while on vandetanib, 2 patients with
normal pretreatment thyroid functions and intact glands
continued to have TFTs within the normal range without
requiring thyroid hormone treatment. Several studies
report that TKIs either induce recurrence of hypothyroidism
in hypothyroid patients, increasing their needs in LT re-
placement, or induce hypothyroidism in patients with previ-
ously normal thyroid function [14,18-20]. In a study looking
at endocrine function in 35 adults with thyroid cancer on
vandetanib, LT dose had to be increased for 26 patients, 5
with differentiated thyroid cancer and 21 with MTC [15].
Similar to our findings with children, none of the three adult
nonthyroidectomized MTC patients needed LT treatment
during the study according to normal serial TSH levels on
vandetanib [15]. Elevated TSH in athyreotic patients may be
due to an indirect effect of vandetanib on the metabolism of
thyroid hormone, or with thyroid hormone action at
the pituitary level. Impaired type-2 iodothyronine deio-
dinase and reduction of T3 generation from T4 at the
pituitary level has been proposed as one alternative
mechanism contributing to the inappropriate elevation
of TSH in patients on TKI, although direct evidence is
lacking [21]. Another hypothesis explaining elevated TSH
in patients on TKIs points towards increased activity of
type 3 deiodinase leading to increased T3 and T4 metabol-
ism as has been demonstrated with other TKIs, including
sorafenib and sunitinib [22,23]. A third mechanism to
explain the increased metabolism of thyroid hormone
by TKIs has been proposed in the case of imatinib.
Imatinib-induced hypothyroidism is thought to involve
induction of uridine diphosphate– glucuronosyltrans-
ferases (UGTs), hepatic enzymes that increase clearance
of T4 and T4. [24] Individuals with intact thyroid glands
are able to compensate and increase T3 generation from
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tution alone, increased TSH results.
Diarrhea (the primary dose limiting toxicity in the
pediatric clinical trial) may have contributed to decreased
thyroid hormone absorption [12,20]. At baseline nine
children had diarrhea while 80% had grade 1–2 diarrhea
[12] during the initial 2 cycles and fewer children pre-
sented diarrhea in advanced stages of the study. Patients
with MEN2B may have intestinal ganglioneuromatosis,
which may play a role in the altered thyroid hormone
absorption. One proxy to screen for malabsorption is
linear growth, however the overall improvement in linear
growth while on vandetanib suggests that malabsorption
of levothyroxine is not the underlying cause of altered
TSH levels.
Conclusions
Clinicians need to be aware of the potential downside of
both over and undertreatment with thyroid hormone to
ensure clinical stability. Compared to previously reported
clinical trial in adults in which increased dosing of LT was
required in 49.3% of athyreotic patients on vandetanib,
91% of athyreotic children in the present study required
increased dosing of LT in order to maintain normal TSH
values. Proper recognition and management of abnormal
thyroid hormone levels is critical in growing children on
TKIs.
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